Inhaled treprostinil for IPF: Patient perspectives

In this video, Prof Benjamin Bondue, head of the ILD clinic at the H.U.B. Erasmus Hospital in Brussels, and patient advocate Chantal Vandendungen shared their views on promising news for idiopathic pulmonary fibrosis (IPF), presented at ERS 2025. 

Ms Vandendungen, a caregiver and representative of patient associations, highlighted the importance of new treatment options for patients and carers. Recent trial results bring hope, especially with emerging drugs such as Nerandomilast and inhaled treprostinil. At ERS 2025, the phase 3 TETON trial of inhaled treprostinil showed significant benefits, including reduced decline in forced vital capacity and diffusion capacity, improved quality of life, fewer adverse events, and slower disease progression. Notably, it is the first inhaled therapy for IPF, directly targeting the lungs while reducing systemic exposure. 

For patients, this represents a major advance, offering a safer and more effective treatment for patients with IPF. Both experts expressed optimism, emphasizing how these results answer long-standing hopes for innovation in IPF care.